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Copyright © 2009 JCBN Summary The aim of the current study was to determine if induction of metallothionein
(MT) via acute or chronic dietary zinc supplementation attenuates intestinal inflammation,
and to investigate the relationship with site-specific intestinal MT determined by immuno-
localization. Growing rats were assigned to zinc-deficient (ZD), acute zinc-treated (ZT), pair-fed,
control or chronic Zn-supplemented (ZS) groups. Half the rats in each dietary group received
5% dextran sulphate sodium (DSS) in their drinking water for 4 days. DSS treatment
produced acute intestinal inflammation in the colon only, however, dietary zinc deficiency,
acute zinc treatment or chronic zinc supplementation did not alter the severity of ulceration.
Serum zinc concentrations were attenuated in the DSS-challenged ZT and ZS groups suggest-
ing that zinc was being utilized in some capacity in response to inflammation. DSS-challenge
induced MT immunostaining in the colonic submucosa, however, MT was not associated with
histological improvements in the present study. The site-specific MT induction in colonic
submucosa during intestinal inflammation requires further clarification as a component of the
host defense.
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Introduction
Zinc (Zn) is an important mineral for both gut immunity
and free radical protection, as both immune and antioxidant
defense systems are impaired in Zn deficiency [1, 2]. Zn
status is compromised in patients with acute inflammatory
bowel disease (IBD) and this may contribute to compromised
defense systems during states of intestinal inflammation
[3–7]. In the small intestine, Zn deficiency promotes
ulceration and inflammation and supplemental dietary Zn
reverses this effect [8]. Oral and intra-rectal Zn treatments
have been shown to reduce colonic inflammation and dis-
ease severity in experimental colitis [9–12].
The mechanisms for the possible protective effects of Zn
during acute intestinal inflammation have not yet been
established. The Zn-ligand, metallothionein (MT) plays a
key role in Zn uptake, distribution, release, storage and
absorption, as well as in free radical scavenging [6, 13, 14].
We have previously demonstrated that MT immunolocaliza-
tion and concentration in the small intestine is responsive
to dietary Zn and localization is cell-type specific [15],
suggesting a role for Zn and MT in gut immunity and
intestinal mucosal turnover. Others have demonstrated that
MT is also located in mucosal epithelium of the colon,
responsive to dietary Zn level, and that MT levels are
attenuated during acute colonic inflammation in both rats
and people [16–18]. Protective effects of Zn, possibly
through MT induction, could reduce apoptosis [19] and
Kruidenier et al. [18] have demonstrated compromised MT
status in inflamed colon from IBD patients, but this was not
necessarily related to the severity of inflammation.
The dextran sulfate sodium (DSS)-induced colitis modelY. Al-Gindan et al.
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exhibits many morphological and pathophysiological features
that resemble human acute intestinal inflammation, including
mucosal damage, superficial ulceration, leukocyte infiltra-
tion and production of cytokines and other inflammatory
mediators [20–23]. Our hypothesis is that acute and chronic
dietary Zn supplementation will attenuate, and conversely
dietary Zn deficiency will exacerbate, intestinal inflam-
mation and injury, and that site-specific induction of MT in
response to Zn may play a protective role. The objectives
were to determine the effects of dietary Zn deficiency,
repletion or supplementation on mucosal injury and inflam-
mation, hematology, trace mineral status, and immunolocal-
ization of MT and caspase-3 (apoptosis marker) in small
intestine and colon during acute DSS-challenge in growing
rats. We evaluated the effects of supplemental dietary Zn in
two ways: chronic Zn supplementation before and during
DSS challenge, and acute Zn treatment of Zn deficient rats
after induction of inflammation (i.e. mimicking clinical
practice whereby Zn treatment may be initiated after the
diagnosis of inflammation).
Materials and Methods
Animals, diet and study design
Sixty-four 3-week old male Sprague Dawley rats (Charles
River, St Constant, PQ) were acclimatized for 5–7 days and
randomly assigned to one of four groups: Zn-deficient (ZD,
n = 32, 3 mg Zn/kg diet), control (C, n = 16, 30 mg Zn/kg
diet), Zn-supplemented (ZS, n = 16, 300 mg Zn/kg diet), or
pair-fed (PF, n = 16, 30 mg Zn/kg diet) for 17 days. The PF
group was given the same amount of feed as consumed by
the ZD rats daily but were provided with the control diet.
The PF group was included to delineate the effects of Zn
deficiency per se, from the malnutrition associated with Zn
deficiency. On day 17, half the rats in each dietary group
(n = 8) received 5% DSS (M.W. 40 KD; MP Biomedicals) in
their drinking water for 4 days. On day 18, (one day after
DSS induction) half of the rats fed the ZD diet were given
the ZS diet for the remaining 3 days and designated the Zn-
treated (ZT) group. Thus, there were n = 8 rats/group either
receiving DSS treatment (ZD+, PF+, ZT+, C+, ZS+) or not
receiving DSS treatment (ZD−, PF−, ZT−, C−, ZS−). All
diets were based on the AIN-93G diet (Table 1) [24]. Feed
cups were refilled 3 times weekly for all groups, except PF
rats were fed daily. Feed consumption was measured and
corrected for spillage.
All rats were housed individually in a controlled environ-
ment (21–23°C; humidity 55%) in a 14:10-h light-dark
cycle. Rats were housed in stainless steel wire-bottom cages
to avoid mineral contamination and to collect feed spillage.
Deionized water was provided in plastic bottles with
stainless steel sipper tubes to avoid mineral contamination.
After DSS induction, water intake was measured daily. Body
weight was measured weekly, and after DSS induction, body
weight and the absence or presence of diarrhea and bloody
stool were measured daily. Animal care was provided in
accordance with a protocol approved by the University of
Manitoba Protocol Management and Review Committee.
Tissue collection
At the end of the study period, rats were euthanized by
CO2 asphyxiation. Body weight, body length and tail length
were recorded. Trunk blood was collected in tubes without
coagulant for serum collection, and in heparinized tubes
for complete blood count (CBC) analysis of plasma
(Hematology Laboratory, Health Sciences Centre, Winnipeg,
Table 1. Diet Formulations
aDiet ingredients were obtained from Harlan Teklad, except the dextrose (Moonshiners) and potassium phosphate (Fisher Scientific)
bAdditional potassium phosphate was added to make the AIN-93M-MX mineral mix equivalent to the AIN-93G-MX mineral mix
c200 mg biotin/kg dextrose; additional biotin due to avidin in egg white, and egg white as the protein source to formulate zinc
deficient diet
d5.775 g zinc carbonate/kg dextrose
Diet Ingredientsa ZD C ZS
(g/kg diet) (3 mg Zn/kg diet) (30 mg Zn/kg diet) (300 mg Zn/kg diet)
Dextrose (cerelose) 603.8 594.6 504.6
Egg white 212.5 212.5 212.5
Fiber (cellulose) 50 50 50
Mineral mix (AIN-93M-MX Zn-free) 35 35 35
Potassium phosphateb 5.4 5.4 5.4
Vitamin mix (AIN-93-VX) 10 10 10
Choline 2.5 2.5 2.5
Biotin mixc 10 10 10
Zn premixd 0.8 10 100
Soybean oil 70 70 70Zinc, MT and Intestinal Inflammation
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MB Canada), and both tubes were immediately placed on
ice. Blood in tubes without coagulant was centrifuged for
8 min at 1400 rpm to separate serum, and the serum was
stored at −80°C.
Small intestine and colon were dissected and weighed,
and length of the small intestine and colon were recorded.
Sections from the mid-point of the small intestine and the
proximal colon were placed in phosphate buffered formalin
and sent to the Pathology Laboratory (Health Sciences
Centre, Winnipeg, MB, Canada) for preparation of paraffin-
embedded blocks and tissue sections for immunohisto-
chemistry and histology. Livers were dissected, weighed,
immediately frozen in liquid nitrogen and stored at −80°C.
Haptoglobin and trace mineral analyses
Haptoglobin was measured using a kit (Tridelta Develop-
ment Ltd). Zn, copper (Cu) and iron (Fe) were assessed
using atomic absorption spectrometry (Varian Spectra AA-
30, Georgetown, ON) after wet-ashing of liver tissue and
appropriate dilution of serum samples.
Histology
Hemotoxylin and eosin stained tissue sections were
prepared from small intestine and colon tissue (Pathology
Laboratory, Health Sciences Centre Winnipeg, MB, Canada).
All slides were blinded, examined microscopically and
scored for inflammation.
MT localization
The procedure for MT immunostaining has been pre-
viously described [15, 25]. Briefly, slides for small intestine
and colon were incubated for 1 h at room temperature with
monoclonal mouse anti-MT antibody (clone E9; Dako,
Carpinteria, CA; diluted 1:25 in phosphate buffered saline).
Prediluted Dako Envision System goat anti-mouse/anti-rabbit
peroxidase labeled polymer was added for 30 min. The
reaction product was visualized with 3,3'-diaminobenzidine
tetrahydrochloride (DAB.4HCL; Polysciences, Warrington,
PA). Tissues were counterstained with Harris hematoxylin
and eosin. Computer images of immunostained sections
were obtained using Nikon Coolscope. Slides were blinded
and viewed at 10× magnification under the microscope. The
intensity of MT staining was estimated using an arbitrary
subjective scale of minuses and pluses according to Jasani &
Elmes [26] as described in the figure legends. Staining
was specific to MT, as staining was absent in all negative
controls.
Apoptosis
Signalstain Cleaved Caspase-3 (ASP 175) IHC Detection
kit (Cell Signaling) was used according to the manufacturer’s
protocol. The slides were blinded and viewed by 10×–40×
magnification. The number of apoptotic cells was counted in
the whole tissue section of small intestine and colon for each
animal. Apoptosis was graded per tissue section as the
number of apoptotic-positive cells: 1–5 cells = low, 5–15
cells = moderate, > 15 cells = elevated apoptosis. The
grading included the mucosa, submucosa and serosa of the
small intestine and the submucosa and crypts of the colon.
Staining was specific to caspase-3, as staining was absent in
all negative controls.
Statistical analysis
Data were analyzed with the Statistical Analysis System
(SAS V9.1 for Windows, SAS Institute Inc., Cary, NC)
using a two-way ANOVA for the main effects of DSS
challenge and diet, and the interaction of DSS x diet.
Duncan’s Multiple Range test was used for means testing.
Chi-sqared analysis was used to detect differences in the
frequency of bloody stool and diarrhea and severity of
inflammation in colon tissue among the DSS-treated groups.
The level of significance was p<0.05. All values were
reported as means ± standard error of the mean (SEM).
Results
Body weight
The animals challenged with DSS had a 5% lower final
body weight compared to the untreated animals (Table 2).
The final body weight of C and ZS groups was ~30% higher
than PF and ZT groups and ~40% higher than the ZD group
which had the lowest final body weight. Even though the ZT
group had the same diet as the ZD group until the last 3 days
of the study when it was changed to Zn-supplemented diet,
the ZT rats had an 8% higher final body weight than the ZD
rats.
Feed and water intake
Before DSS challenge, the C and ZS rats consumed more
feed than the ZD, PF and ZT rats (Table 2). DSS challenge
had an inhibitory effect on feed intake, as the DSS+ rats
consumed 33% less feed than the DSS− rats. After DSS
challenge, the ZT group did not have a different feed intake
compared to the C and ZS groups, while the feed intake of
the ZD and PF groups remained lower.
There was no effect of DSS on water intake (Table 2). The
ZD, PF and ZT rats had lower water intake compared to the
C and ZS rats, however, when water intake was corrected for
body weight, only the PF group had reduced water intake.
Stool characteristics
The groups exposed to DSS challenge had diarrhea and
bloody stool starting one day after giving the rats 5% DSS in
the drinking water (data not shown). By day 2, the PF and ZS
groups had the worst bloody stool and diarrhea, respectively,
and by day 3, these groups both had more bloody stool andY. Al-Gindan et al.
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diarrhea than the other groups. By day 4, all groups had the
same severity of bloody stool and diarrhea.
Small intestine and colon weights and lengths
The DSS challenged rats had 1.3 fold greater small
intestine/body weight ratio but no difference in small
intestine length (Table 2) compared to the unchallenged
rats. The small intestine/body weight ratio of ZD, PF and C
rats was not different. However, the ZT rats had a 1.3 fold
higher small intestine/body weight ratio than ZD, PF and C
rats. The small intestine of C and the ZS groups was longer
than ZD, PF, and ZT rats.
The DSS challenged group had a 1.2 fold lower colon
weight/body weight ratio than the untreated rats (Table 2).
The ZD, PF and ZT groups had a higher colon weight/body
weight ratio than C and ZS rats. However, colon length was
less in the DSS challenged rats than the unchallenged rats.
Complete blood count
The DSS-challenged rats had lower red blood cells
(RBC), hemoglobin (Hgb), mean corpuscular hemoglobin
(MCH) and mean corpuscular hemoglobin concentration
(MCHC) counts and higher white blood cell (WBC),
lymphocyte and neutrophil counts than the unchallenged rats
(Table 3). Hematocrit (Hct), mean cell volume (MCV),
monocytes and platelets were not affected by DSS challenge.
The ZD and PF rats had a higher RBC and Hgb counts than
ZT, C and ZS groups. The ZD rats had higher Hct levels than
ZT and ZS rats. The hematocrit of ZD rats was not different
from PF or C rats. The hematocrit of ZT groups was lower
than ZD, PF and C groups. ZD, PF and ZT rats had a lower
MCV than the C and ZS rats. The C group had the highest
MCH, while the ZD, PF, and ZT rats had higher MCHC
values compared to C and ZS rats. The lymphocyte counts
were higher in the ZS group compared to PF and ZT groups.
There were no differences in WBC, neutrophils, monocytes
or platelets due to diet.
Serum haptoglobin and Zn
DSS-challenged C and ZS rats had 2-fold greater serum
haptoglobin concentrations compared to the other groups
(Fig. 1A). In unchallenged rats, the ZD group had a 84%
lower serum Zn concentration compared to PF and C rats,
and the serum Zn of ZS rats was 69% higher than C rats
(Fig. 1B). The 3 day Zn repletion of ZT rats elevated serum
Zn 8-fold compared to ZD rats and 1.3-fold compared to C
rats. With DSS challenge, ZD rats still had the lowest serum
Zn compared to all other groups. However, the elevation of
serum Zn in the ZT+ group was attenuated compared to the
ZT− group, and the elevation of serum Zn in the ZS+ group
was attenuated compared to the ZS− group.
Liver trace mineral assessment
DSS challenge did not affect liver Zn and Fe concentra-
tion (Fig. 2A, C) but DSS challenged rats had an 18% lower
liver Cu concentration than the unchallenged rats (Fig. 2B).
The ZD and C groups had a ~15% lower liver Zn concentra-
tion compared to PF and ZT groups, while the ZS group was
not different from any of the other groups. The PF rats had
the highest liver Cu concentration while the ZS rats had the
lowest. The ZD and C rats had a similar liver Cu concentra-
tion that was elevated compared to the ZT group. Liver Fe
was elevated ~1.5 fold in ZD rats compared to PF and ZT
rats, and was elevated 1.6 fold in PF compared to C. The C
Table 2. Effect of DSS challenge or diet on anthropometric and oral intake dataa
aValues are means ± SEM, significant p values <0.05.
bDSS Challenge: DSS− = no dextran sulfate sodium challenge, DSS+ = 5% dextran sulfate sodium challenge, n = 40/group.
cDiet: ZD = zinc deficient (3 mg/kg zinc), PF = pair fed (30 mg/kg zinc) to match energy intake of ZD group, ZT = zinc deficient (3 mg/
kg zinc) and repleted (300 mg/kg zinc), C = control (30 mg/kg zinc), ZS = zinc supplemented (300 mg/kg zinc), n = 16/group.
dInteraction effects of DSS challenge × diet were not significant, therefore the data are presented as main effects for DSS Treatment and Diet.
DSS Treatmentb Dietc DSS × Dietd
DSS+ DSS− p ZD PF ZT C ZS pp
Final body weight (g) 244 ± 6 256 ± 7 0.0003 208 ± 4c 230 ± 5b 225 ± 5b 295 ± 4a 294 ± 6a <0.0001 NS
Feed intake before DSS challenge (g) 419 ± 9 417 ± 9 NS 380 ± 10b 390 ± 11b 378 ± 10b 474 ± 10a 468 ± 6a <0.0001 NS
Feed intake after DSS challenge (g) 51 ± 36 8 ± 4 <0.0001 46 ± 3b 41 ± 2b 69 ± 8a 69 ± 6a 72 ± 5a <0.0001 NS
Water intake (g) 118 ± 7 124 ± 9N S 1 1 0 ± 9b 94 ± 5b 113 ± 7b 151 ± 8a 139 ± 8a <0.0001 NS
Water intake (g/g body weight) 0.48 ± 0.02 0.48 ± 0.02 NS 0.52 ± 0.04a 0.4 ± 0.02b 0.51 ± 0.03a 0.51 ± 0.03a 0.48 ± 0.03ab 0.0464 NS
Small intestine weight (g) 9.61 ± 0.32 8.02 ± 0.30 <0.0001 6.96 ± 0.37c 7.58 ± 0.47c 8.81 ± 0.37b 10.07 ± 0.33a 10.64 ± 0.43a <0.0001 NS
Small intestine weight 
(g/g body weight)
0.0393 ± 0.0008 0.0312 ± 0.0007 <0.0001 0.0332 ± 0.0013b 0.0330 ± 0.0019b 0.0392 ± 0.0015a 0.0343 ± 0.0013b 0.0364 ± 0.0015ab 0.0006 NS
Small intestine length (cm) 52.7 ± 0.6 52.2 ± 0.7 NS 49.5 ± 0.5b 51.6 ± 0.9b 49.4 ± 0.8b 55.3 ± 0.7a 56.4 ± 0.9a <0.0001 NS
Colon weight (g) 1.71 ± 0.07 2.22 ± 0.08 <0.0001 1.83 ± 0.14 2.14 ± 0.12 2.03 ± 0.14 1.8 ± 0.11 2.03 ± 0.16 NS NS
Colon weight (g/g body weight) 0.0072 ± 0.0004 0.0089 ± 0.0004 0.0004 0.0089 ± 0.0006a 0.0094 ± 0.0005a 0.0090 ± 0.0005a 0.0061 ± 0.0003b 0.0068 ± 0.0005b <0.0001 NS
Colon length (cm) 13.7 ± 3.1 12.9 ± 0.3 NS 10.8 ± 0.4 12.1 ± 0.5 11.7 ± 0.6 11.7 ± 0.5 12.5 ± 0.5 NS NSZinc, MT and Intestinal Inflammation
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and ZS rats had similar liver Fe concentrations. The 3 days
of Zn supplementation reduced liver Fe of the ZT group to a
level equivalent to the PF group.
Histology
(i) small intestine. In the small intestine, neither DSS or
dietary treatment affected the histology (Fig. 3A, B).
(ii) colon. In the colon, all rats challenged with DSS
showed colonic inflammation and there were no differences
in the degree of inflammation among dietary groups (data
not shown). Unexpectedly in the colon, some of the unchal-
lenged rats had indications of quiescent nonspecific chronic
inflammation represented by focal submucosal infiltration
by mononuclear inflammatory cells, mainly lymphocytes,
which sometimes extended to the deeper parts of the mucosa
leading to atrophy of the overlying mucosa. However,
mucosal changes indicative of active inflammation, namely,
significant neutrophilic and eosinophilic infiltration, crypt
abscesses and ulceration were not seen in untreated rats. The
DSS-challenged cases showed focal mucosal changes of
variable severity, consisting of edema, congestion and
significant infiltration of the lamina propria by neutrophils
and eosinophils, in addition to mononuclear inflammatory
cells (Fig. 3C). The inflammatory infiltrate in the mucosa
extended to the submucosa in the more severe cases.
Variable numbers of crypt abscesses (Fig. 3D black arrow)
were also seen, appearing as dilated crypts lined by flattened
epithelium devoid of goblet cells, and containing intra-
luminal neutrophilic aggregates. There was also variable
focal goblet cell depletion (Fig. 3D white arrow), as well as
crypt loss and/or mucosal ulcers that varied in extent
(Fig. 3E). The crypt epithelium adjoining the ulceration
often showed regenerative hyperplasia. The submucosa
showed an extensive, dense, predominantly lymphocytic
mononuclear inflammatory cell infiltrate that focally
extended to the mucosa, a finding comparable to that noted
in control and untreated animals (Fig. 3F).
MT localization
(i) Small intestine. Moderate to strong cytoplasmic and
nuclear MT staining of Paneth cells (PC), surface epithelial
cells (SEC), goblet cells (GC) and lamina propria (LP) was
present in all groups with the exception of the ZD group
which had no to very weak (one to two cells only) MT
staining (Fig. 4A, B). The strongest and the most consistent
MT immunostaining of Paneth cells, surface epithelial cells,
goblet cells and lamina propria was seen in the unchallenged
ZS rats (Fig. 4J). There was strong MT immunostaining in
Paneth cells and moderate immunostaining in surface
epithelial cells, goblet cells and lamina propria in all other
groups except the ZD rats which had very weak to no detect-
able MT immunostaining (Fig. 4).
(ii) Colon. MT immunostaining was nondetectable in the
unchallenged ZD group whereas it was very weak in the
submucosa of the DSS-challenged ZD rats (Fig. 5A, B). All
other DSS-challenged rats had MT staining in the crypts and
submucosa (Fig. 5C, E, G, I), while the non-challenged rats
had MT immunostaining only in the crypts (Fig. 5D, F, H, J).
The strongest crypt staining was seen in the unchallenged
ZT rats (Fig. 5F) and the unchallenged ZS rats (Fig. 5J).
There was strong submucosal staining in the DSS-challenged
PF, ZT, C and ZS rats (Fig. 5C, E, G, I, respectively).
Table 3. Effect of DSS challenge or diet on complete blood count of ratsa
aValues are means ± SEM, significant p values <0.05.
bDSS Challenge: DSS– = no dextran sulfate sodium challenge, DSS+ = 5% dextran sulfate sodium challenge, n = 40/group.
cDiet: ZD = zinc deficient (3 mg/kg zinc), PF = pair fed (30 mg/kg zinc) to match energy intake of ZD group, ZT = zinc deficient (3 mg/kg
zinc) and repleted (300 mg/kg zinc), C = control (30 mg/kg zinc), ZS = zinc supplemented (300 mg/kg zinc), n = 16/group.
dInteraction effects of DSS challenge × diet were not significant, therefore the data are presented as main effects for DSS Treatment and Diet
DSS Challengeb Dietc DSS × Dietd
DSS+ DSS− pZ D P F Z T C Z Spp
RBC (1012/L) 6.64 ± 0.15 6.94 ± 0.10 0.0393 7.61 ± 0.11a 7.19 ± 0.14a 6.45 ± 0.20b 6.43 ± 0.11b 6.31 ± 0.17b <0.0001 NS
Hemoglobin (g/L) 138 ± 31 4 6 ± 2 0.0069 157 ± 3a 148 ± 4a 133 ± 4b 139 ± 2b 132 ± 4b <0.0001 NS
Hematocrit (L) 0.464 ± 0.009 0.472 ± 0.009 NS 0.507 ± 0.013a 0.486 ± 0.010ab 0.431 ± 0.015c 0.471 ± 0.013ab 0.45 ± 0.014bc 0.0009 NS
MCV (109/L) 69.5 ± 0.8 68.2 ± 0.4 0.0584 66.9 ± 0.5b 67 ± 0.6b 67.2 ± 0.4b 72.7 ± 1.1a 70.6 ± 1.1a <0.0001 NS
MCH (109/L) 20.7 ± 0.1 21 ± 0.1 0.0324 20.7 ± 0.2b 20.7 ± 0.2b 20.6 ± 0.2b 21.5 ± 0.1a 21 ± 0.2b 0.0009 NS
MCHC (109/L) 298.8 ± 2.2 308.8 ± 1.3 <0.0001 308.9 ± 2.0a 308.6 ± 2.5a 306.3 ± 2.3a 296.8 ± 3.4b 297.9 ± 3.8b 0.0007 NS
WBC (109/L) 22.7 ± 1.3 12.7 ± 0.7 <0.0001 16.7 ± 1.9 15.7 ± 2.5 17.7 ± 2.3 17.1 ± 1.7 20.9 ± 2.0 NS NS
Lymphocytes (109/L) 17.9 ± 1.2 11.1 ± 0.7 <0.0001 14.3 ± 1.5ab 12.4 ± 2.3b 12.2 ± 1.5b 16.2 ± 1.2ab 17.7 ± 1.9a 0.0352 NS
Neutrophils(109/L) 3.74 ± 0.24 1.18 ± 0.26 <0.0001 2.28 ± 0.52 2.84 ± 0.73 2.47 ± 0.52 2.07 ± 0.41 2.57 ± 0.40 NS NS
Monocytes (109/L) 0.46 ± 0.01 0.30 ± 0.05 NS 0.34 ± 0.08 0.16 ± 0.07 0.42 ± 0.14 0.5 ± 0.14 0.49 ± 0.15 NS NS
Platelets (109/L) 717 ± 20 778 ± 25 NS 759 ± 33 771 ± 42 661 ± 37 766 ± 23 792 ± 38 NS NSY. Al-Gindan et al.
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Apoptosis (caspase-3) immunohistochemistry
(i) Small intestine. The DSS-challenged ZD, PF and ZT
rats had elevated apoptosis based on caspase-3 immuno-
staining compared to their respective unchallenged counter-
parts (images not shown). Caspase-3 immunostaining was
lowest in ZS rats and moderate in C rats, regardless of DSS
treatment.
(ii) Colon. DSS challenge increased caspase-3 immuno-
staining in ZT, PF and C rats but had no effect in ZD rats,
while caspase-3 immunostaining was lower in DSS-
challenged ZS rats compared to unchallenged ZS rats.
Discussion
Administration of 5% DSS in the drinking water of rats
for 4 days produced moderate to severe colonic inflamma-
tion but contrary to our hypothesis, it was not exacerbated by
dietary Zn deficiency, nor was it reduced by acute Zn
treatment or chronic Zn supplementation via the diet. Others
providing Zn dose-dependently by oral gavage or by enema
Fig. 1. Effects of DSS challenge and dietary zinc on the serum
haptoglobin (A) and zinc (B) status of rats. Values are
means ± SEM. − = no dextran sulfate sodium challenge,
+ = 5% dextran sulfate sodium challenge, n =8 /
DSS × diet group; ZD = zinc deficient (3 mg/kg zinc),
PF = pair fed (30 mg/kg zinc) to match energy intake
of ZD group, ZT = zinc deficient (3 mg/kg zinc) and
repleted (300 mg/kg zinc), C = control (30 mg/kg zinc),
ZS = zinc supplemented (300 mg/kg zinc); different
letters indicate significant differences between DSS × diet
groups (p<0.05).
Fig. 2. Effects of DSS challenge or dietary zinc on the liver
trace mineral status of rats. Liver zinc (A), copper (B)
and iron (C). Values are means ± SEM. − = no dextran
sulfate sodium challenge, + = 5% dextran sulfate sodium
challenge, n = 40/group DSS group; ZD = zinc deficient
(3 mg/kg zinc), PF = pair fed (30 mg/kg zinc) to match
energy intake of ZD group, ZT = zinc deficient (3 mg/kg
zinc) and repleted (300 mg/kg zinc), C = control (30
mg/kg zinc), ZS = zinc supplemented (300 mg/kg zinc),
n = 16/group; * = DSS− different from DSS+; different
letters indicate significant differences between diet
groups (p<0.05).Zinc, MT and Intestinal Inflammation
Vol. 44, No. 2, 2009
137
have noted protective effects of zinc on colitis disease
activity index and tissue damage [9, 11, 12]. In rats with
dinitrobenzene-sulphonic acid (DNBS)-induced colitis, intra-
rectal zinc was a more effective treatment than oral zinc [11].
These findings indicate that the route of zinc administration
appears important, with local administration being more
effective and dietary supplementation least effective in
experimental models of acute intestinal inflammation.
MT immunostaining was responsive to dietary zinc. In the
small intestine, MT immunostaining was absent or very
weak in the ZD rats and highest in ZS rats (Fig. 4). This is in
agreement with other studies assessing MT by immuno-
histochemistry and cadmium hemoglobin affinity assay [15,
26,  27]. Furthermore, dietary Zn induced MT in small
intestine as early as 24-h after Zn repletion [15] and thus if
colonic tissue responds similarly, MT would be present for
protection against DSS-challenge in ZT and ZS rats in the
present study. In the colon, the site of inflammation, MT
immunostaining was strongest in the ZT and ZS groups
(Fig. 5), showing that acute and chronic Zn supplementation
enhances MT localization in the colon. Interestingly, only
the DSS-challenged animals had MT localization in the
submocosa of the colon (Fig. 5), suggesting the type of injury
and inflammation caused by DSS induces a site-specific
response of MT in the submucosa. Conversely, DiLeo et al.
[16] showed an attenuated MT concentration in the colonic
Fig. 3. Small intestine and colon histology. In the small intestine note normal histology (A–B, 10× and 40× magnification, respectively).
In the colon note ulceration (C black arrow), congestion (C white arrow, 20× magnification), crypt abscesses (D black arrow),
goblet cell depletion (D white arrow, 10× magnification), loss of crypts (E black arrow), goblet cell depletion, infiltration of
inflammatory cells, regenerative hyperplasia of crypt epithelium, and flattening of crypt lining (E white arrow, 10× magnifica-
tion), lymphocytic aggregates in the submocusa extending to the mucosa (F black arrow) and loss of crypts (F white arrow, 10×
magnification).Y. Al-Gindan et al.
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mucosa of DNBS-induced colitis. However, neither the cur-
rent study or others, including those using MT-null, MT-
knockout or MT-transgenic mice have been able to demon-
strate a beneficial effect of MT on macroscopic inflamma-
tion or colitis severity with administration of zinc by oral or
intra-rectal routes [12, 16, 28]. Although zinc may be an ef-
fective treatment in models of colitis, it does not appear that
MT is central to the protective mechanism, and the question
remains as to why MT was induced in the colonic submucosa
of DSS-treated rats.
Fig. 4. Small intestinal metallothionein localization. Metal-
lothionein was absent in the ZD groups (A–B) and
present in all other groups (C–J) as indicated by scoring:
(−−) none to very few cells, (+) mild, (++) moderate,
(+++) high. PC = Paneth cells, SEC = surface epithelial
cells, GC = goblet cells and LP = lamina propria. DSS– =
no dextran sulfate sodium challenge, DSS+ = 5%
dextran sulfate sodium challenge; ZD = zinc deficient
(3 mg/kg zinc), PF = pair fed (30 mg/kg zinc) to match
energy intake of ZD group, ZT = zinc deficient (3 mg/kg
zinc) and repleted (300 mg/kg zinc), C = control (30 mg/
kg zinc), ZS = zinc supplemented (300 mg/kg zinc). All
slides 10× magnification.
Fig. 5. Colonic metallothionein localization. Metallothionein
staining was weak in the submucosa of the ZD+ group
(A), absent in the ZD− group (B); all other DSS+ groups
had staining in the submucosa and crypts (C, E, G, I)
while the DSS− groups had staining only in the crypts
(D, F, H, J) as indicated by scoring: (−−) none to very
weak, (+) mild, (++) moderate, (+++) high of submocosa
and crypts. − = no dextran sulfate sodium challenge,
+ = 5% dextran sulfate sodium challenge; ZD = zinc
deficient (3 mg/kg zinc), PF = pair fed (30 mg/kg zinc)
to match energy intake of ZD group, ZT = zinc deficient
(3 mg/kg zinc) and repleted (300 mg/kg zinc), C = control
(30 mg/kg zinc), ZS = zinc supplemented (300 mg/kg
zinc).Zinc, MT and Intestinal Inflammation
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Dietary Zn did not affect DSS dose, however, calorie
restriction (PF group) resulted in lower water intake
corrected for body weight and thus DSS dose (Table 2). DSS
challenge produced reddish anus and bloody diarrhea,
reduced feed intake, 5% lower body weight (Table 2), and
colonic (but not small intestinal) inflammation consisting of
significant infiltration of white blood cells, crypt abscess,
mucosal ulcers, goblet cell depletion, edema and congestion
(Fig. 3) compared to the untreated rats, in agreement with
other studies [6,  29–33]. Although both DSS- and non-
challenged rats had quiescent inflammatory cell infiltrates in
the small intestine and colon, the overall level of active
inflammation was significantly elevated in the DSS-
challenged rats. The greater weight loss in the DSS-
challenged rats may have been due to the intestinal inflam-
mation and diarrhea causing dehydration, along with
reduced feed intake, consistent with other reports of DSS-
induced inflammation [21,  34]. The rats challenged with
DSS also had lower red blood cell and hemoglobin levels
(Table 3) compared to the non-challenged groups, likely due
to the diarrheal blood loss, again consistent with previous
reports using similar DSS treatment [35]. Fewer red blood
cells and a lower concentration of hemoglobin could reduce
the amount of oxygen transported to the cells to metabolize
energy, thus, making it more difficult to maintain growth.
Furthermore, MCH and MCHC were slightly reduced in the
DSS-challenged rats which indicated that the rats were
hypochromic compared to the control rats. White blood cell
count, lymphocyte count and neutrophils were significantly
higher in the DSS challenged rats (Table 3) obviously due to
inflammation.
Serum Zn concentrations were responsive to dietary Zn
level, including in those rats with intestinal inflammation
(Fig. 1B). It is interesting to point out, however, that the
serum Zn response to supplementation (ZT and ZS groups)
was attenuated during DSS-challenge, suggesting that Zn
was utilized in some capacity in response to acute inflam-
mation. It is possible that there was less zinc absorption
during the inflammatory challenge in these groups, however
zinc is mostly absorbed in the small intestine where there
was not inflammation and all the DSS-treated groups
displayed inflammation while only the ZT and ZS groups
had lower serum zinc concentrations compared to their
untreated counterparts.
Zn status also affected the CBC; the red blood cell count
and the hemoglobin levels were higher due to Zn and energy
deficiency (ZD and PF rats, respectively) compared to the
control and Zn supplemented groups (Table 3) and in agree-
ment with previous work, suggesting altered hematological
development due to Zn deficiency in young rats [36]. In
contrast, El-Hendy et al. [37] found that longer term Zn
deficiency in growing rats produced a 17% decline in the
hemoglobin levels and they attributed it to a reduction in
the rate of red blood cell formation. Short term Zn treatment
(ZT group) was not adequate to protect against declines in
MCV and MCH. There did not seem to be differences in
inflammation between dietary Zn treatment groups based on
WBC and neutrophils, although lymphocytes were higher in
ZS rats compared to ZT and PF rats.
There are similarities in the absorption and transport of
Zn, Cu and Fe, thus it was not surprising that liver
concentrations of these minerals were affected by both DSS
challenge and dietary Zn manipulation. DSS-challenge
resulted in 15% lower liver Cu but did not affect liver Zn
or Fe (Fig. 2B, A, C, respectively). Acute and chronic Zn
supplementation produced lower levels of liver Cu in the ZS
and ZT rats presumably due to reduced intestinal Cu absorp-
tion [38]. PF rats had elevated liver Zn, Cu and Fe compared
to C rats, likely due to the energy restriction and con-
sequential developmental delay. Liver Fe was highest in ZD
rats compared to both energy restricted and control rats,
as shown previously [39], implying that Zn deficiency
increases Fe absorption. Even short-term zinc supplementa-
tion (3 days) reduced liver Fe concentration in the ZT group
but long-term Zn-supplementation did not alter liver Fe
levels. From this we conclude that supplementation with
300 mg Zn/kg did not adversely affect iron absorption,
however, Zn deficiency may be associated with increased
Fe absorption.
Zn deficiency is associated with more apoptosis, parti-
cularly in organs with elevated cell turnover [40–42], thus
we wanted to explore whether DSS-challenge and dietary Zn
manipulation was affecting caspase-3 immunostaining in
small intestine and colon. However, due to the nature of the
apoptotic process, there are relatively few cells undergoing
apoptosis at any one time and this makes detection and
interpretation difficult. The pattern of caspase-3 immuno-
staining differed in the small intestine and the colon in
response to dietary zinc and DSS challenge. Although our
immunostaining results in the small intestine may indicate
a reduction of caspase-3 with Zn supplementation and
enhancement with Zn deficiency, we did not observe this
pattern in the colon which was the site of inflammation.
These preliminary results require further investigation with
additional measures of apoptosis.
In summary, 5% DSS treatment in rats produced acute
colonic inflammation but dietary Zn deficiency, acute treat-
ment or chronic supplementation did not alter the severity of
ulceration in the colon. MT immunostaining in the colon
responded to dietary Zn manipulations similarly to the small
intestine. Furthermore, DSS-challenge induced MT immuno-
staining in the colonic submucosa. Site-specific MT induc-
tion in colonic submucosa during acute intestinal inflam-
mation may be an important component of the host defense
and requires further investigation to determine its potential
protective role in various intestinal inflammatory diseases.Y. Al-Gindan et al.
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